Gamze ÇELMELİ, Doğa TÜRKKAHRAMAN, Fatih ÇELMELİ, Aslı ADANIR SÜRER

Montelukast Kullanımı Sonrası İnti̇ har Düşüncesi̇ ve Davranışı Olg Gösteren

Bir lökotrien reseptör antagonisti olan montelukast çocukluk çağı astım tedavisinde sıklıkla kullanılan bir ajandır. İlacın çeşitlinöropsikiyatrik yan etkileri giderek artan bir şekilde rapor edilmektedir. Bu olgu sunumunda, daha öncesinde genetik yat- kınlığı ve psikolojik sorunu olmayan, montelukast kullanımı sonrası depresyon ve intihar düşüncesi/davranışı sergileyen, ilaçkesilmesi ile yakınmaları tamamen kaybolan bir olguyu rapor ediyoruz.

Suicide Behaviour After Montelukast Usage: A Case Report

Montelukast, a leukotriene receptor antagonistis a commonly prescribed medication in management of asthma inchildren. It has been associated with increased risk of various neuropsychiatric events. Here, we report a young boywho presents a number of unusual neuropsychiatric events (suicide behavior) after montelukast usage. The completeresolution of the symptoms was seen upon the withdrawal of the medication.

PDF

___

1. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31: 143-78.
2. Full Drug Prescribing information, MERCK & CO., INC. available at www.singulair.com/montelukast_sodium/hcp/asthma/prescribing- information.jsp accessed 17/09/10.
3. Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:699-706.
4. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. Engl J Med 1998;339:147-52.
5. Leukotriene inhibitors: Montelukast (marketed as Singulair), zaﬁ rlukast (marketed as Accolate), and zileuton (marketed as Zyﬂ o and Zyﬂ o CR). Healthcare Professional Sheet, Washington (DC): US Food and Drug Administration; 2009. Available from: http:// www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s0 51_020830s052_021409s028lbl.pdf.
6. Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009;44:568-79.
7. Wallerstedt SM, Brunlof G, Sundstrom A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009;18:858-64.
8. Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691-6.
9. Skillman KL, Stumpf JL. Montelukast-induced anxiety in two pediatric patients. Pharmacotherapy 2011;31:524
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45